Safety and Efficacy of Jaktinib in JAK Inhibitor–Naïve Patients With Myelofibrosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
American Journal of Hematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Efficacy of Jaktinib in the Treatment of Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis: Results of a Phase II Trial
Am. J. Hematol 2022 Aug 28;[EPub Ahead of Print], Y Zhang, H Zhou, Z Jiang, D Wu, J Zhuang, W Li, Q Jiang, X Wang, J Huang, H Zhu, L Yang, X Du, L Fei, R Xia, F Zhang, J Hu, Y Li, Y Hu, J Liu, C Jin, K Sun, Z Zhou, L Wu, W Yu, J JinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.